September 24, 2007 15:30 ET

MEDRAD Supports National Prostate Cancer Coalition With Materials to Educate Men About Prostate MR Imaging

WARRENDALE, PA--(Marketwire - September 24, 2007) - Medical device maker MEDRAD, INC. has partnered with the National Prostate Cancer Coalition (NPCC) to provide information about prostate magnetic resonance (MR) imaging to thousands of men who participate in NPCC's free mobile screening program.

MEDRAD markets an endorectal coil for use in prostate MR that provides very accurate pictures of the prostate to assist physicians in diagnosing and staging cancer and planning treatment options. MEDRAD will contribute educational materials about prostate MR, including animation demonstrating the procedure, physician interviews, medical images, a list of hospitals offering the procedure, and other information.

"Providing information directly to patients is a relatively new effort for MEDRAD, but it is a natural extension of our goal to improve the quality of healthcare," said Joe Havrilla, senior vice president, MEDRAD MR Business Unit. "This partnership with NPCC will broaden awareness of prostate MR, an exciting new medical technology that can make a difference in the lives of prostate cancer patients."

Prostate cancer is a growing problem for American men with estimates that one of every six men will get prostate cancer in their lifetime. NPCC is at the forefront in the fight against this disease. In addition to offering free prostate cancer screenings with the Drive Against Prostate Cancer mobile screening program, NPCC offers men and their families prostate cancer information and resources through their Web site,, and a weekly electronic newsletter, AWARE.

"NPCC welcomes all support in achieving our mission to reduce the burden of prostate cancer on American men and their families through awareness, outreach, and advocacy," said NPCC CEO Richard N. Atkins, M.D. "We are thrilled to partner with MEDRAD to fight against prostate cancer through education of advanced MR technology and other treatment options."

About the National Prostate Cancer Coalition

The National Prostate Cancer Coalition ( is a non-profit organization that sets the standard for rapidly reducing the burden of prostate cancer on American men and their families through awareness, outreach, and advocacy.


MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2006 revenues were $478 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at

Cautionary statement regarding forward-looking statements.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

Contact Information

  • For additional information contact:
    Dan Dieter
    MEDRAD Marketing Services
    Email Contact

    Brooke Saltzer
    National Prostate Cancer Coalition
    Email Contact